Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MERCK & CO., INC.

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Communiqués de presse de la société MERCK & CO., INC.
01/21Strides and its African subsidiary Universal Corporation partner with Medicines Patent
AQ
01/21Eisai - Results From Pivotal Phase 3 Study 309/KEYNOTE-775 Trial of LENVIMA (lenvatinib..
AQ
01/21Merck - RESULTS FROM PIVOTAL PHASE 3 KEYNOTE-775/STUDY 309 TRIAL OF KEYTRUDA (PEMBROLIZ..
AQ
01/20Merck's $1.4 Billion Insurance Win won't be possible any more with Lloyd's cyber war ex..
AQ
01/20Results From Pivotal Phase 3 KEYNOTE-775/Study 309 Trial of KEYTRUDA® (pembrolizumab) P..
BU
01/20Frank Clyburn to Leave Merck
BU
01/19Merck's KEYTRUDA (pembrolizumab) Significantly Improved Overall Survival (OS) Versus Pl..
AQ
01/18Merck's KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Versus P..
BU
01/18Merck and Ridgeback Announce Supply Agreement with UNICEF for Molnupiravir, an Investig..
BU
01/11Merck's KEYTRUDA (pembrolizumab) Showed Statistically Significant Improvement in Diseas..
AQ
01/11Gilead Announces Clinical Trial Collaborations With Merck to Evaluate Trodelvy in Combi..
AQ
01/10Merck to Hold Fourth-Quarter and Full-Year 2021 Sales and Earnings Conference Call on F..
AQ
01/10Merck's KEYTRUDA® (pembrolizumab) Showed Statistically Significant Improvement in Disea..
BU
01/07Merck to Hold Fourth-Quarter and Full-Year 2021 Sales and Earnings Conference Call on F..
BU
01/06Noxxon provides update on evaluation of nox-a12 in non- oncology indication by a leadin..
AQ
01/06Imv announces finalization of the basket clinical study in collaboration with merck and..
AQ
01/06Thinking about trading options or stock in Dicks Sporting Goods, Laredo Petroleum, Bank..
PR
01/04Merck to Present at the 40th Annual J.P. Morgan Healthcare Conference
BU
01/04Vaccinex Reports Phase Ib KEYNOTE B84 Combination Study of Keytruda® and Pepinemab in P..
AQ
01/04Why 2022 Could Open Gangbusters for Covid Stocks (AZN, OTLC, NVAX, PFE, MRNA, MRK, JNJ,..
AQ
2021Dr. Reddy's Laboratories receives DCGI approval to launch Molnupiravir capsules 200mg (..
AQ
2021KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Approved in Japan for Patients Wit..
BU
2021KYODO NEWS DIGEST : Dec. 25, 2021 -1-
AQ
2021LIVE UPDATES : Outbreak recorded on Florida-based cruise ship
AQ
2021Merck and Ridgeback's Molnupiravir, an Investigational Oral Antiviral COVID-19 Treatmen..
BU
2021KYODO NEWS DIGEST : Dec. 24, 2021 -3-
AQ
2021Merck and Ridgeback's Molnupiravir Receives U.S. FDA Emergency Use Authorization for th..
AQ
2021U.S. regulators authorize 2nd oral antiviral COVID-19 pill
AQ
2021Merck and Ridgeback's Molnupiravir Receives U.S. FDA Emergency Use Authorization for th..
BU
2021Merck and Ridgeback Announce U.K. Government to Purchase Additional 1.75 Million Course..
BU
2021Merck Receives Positive EU CHMP Opinion for KEYTRUDA (pembrolizumab) as Adjuvant Therap..
AQ
2021Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as Adjuvant Thera..
BU
2021Merck and Ridgeback Announce Publication of Phase 3 Study of Molnupiravir, an Investiga..
BU
2021European Commission Approves Merck's VAXNEUVANCE (Pneumococcal 15-valent Conjugate Vacc..
AQ
2021ADDING and REPLACING European Commission Approves Merck's VAXNEUVANCE™ (Pneumococ..
BU
2021Purple Innovation, Sunrun fall; Alcoa, Terminix rise
AQ
2021Merck Announces Clinical Holds on Studies Evaluating Islatravir for the Treatment and P..
BU
2021Merck Issues $1 Billion Inaugural Sustainability Bond
BU
2021MERCK & CO., INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2021Top Ideas in the Small Cap Biotech Space (INMB, OTLC, DVAX, SAVA, ICPT, IMGN)
AQ
2021Merck Prices $8.0 Billion Debt Offering
BU
2021Merck Announces Additional $150M Investment Through 2025 to Help End Maternal Mortality..
BU
2021NGM Bio Announces Clinical Trial Collaboration with Merck Related to Ongoing Phase 1/2 ..
AQ
2021Merck Announces Pause in Enrollment for Two Phase 3 Clinical Trials of Investigational,..
AQ
2021Merck Announces Pause in Enrollment for Two Phase 3 Clinical Trials of Investigational,..
BU
2021Merck Canada Announces Expansion of Manufacturing for Molnupiravir, an Investigational ..
AQ
2021FDA Approves Merck's KEYTRUDA as Adjuvant Treatment for Adult and Pediatric Patients Wi..
AQ
2021FDA Approves Merck's KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Pedi..
BU
2021Merck Canada Announces Supply Agreement of Up to 1 Million Patient Courses of Molnupira..
AQ
2021KYODO NEWS DIGEST : Dec. 3, 2021 -3-
AQ
2021Biotech Growth Stocks Set to Benefit from Rising Volatility (REGN, OTLC, AMGN, ILMN, LL..
AQ
2021U.S. pharma Merck unit seeks Japan's approval of oral COVID drug
AQ
2021Tokyo stocks end higher on hopes for COVID-19 oral treatment drug
AQ
2021U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for..
AQ
2021Federal Court Of Appeal Dismisses Appeal, Upholds Strict Interpretation Of Patent Listi..
AQ
2021U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for..
BU
2021Merck and Ridgeback Statement on Positive FDA Advisory Committee Vote for Investigation..
BU
2021Merck Announces First-Quarter 2022 Dividend
BU
2021Merck's KEYTRUDA® (pembrolizumab) Approved in Japan in Combination With Chemotherapy fo..
BU
2021FDA Accepts Regulatory Submission of Supplemental New Drug Application for LYNPARZA® (o..
BU
2021Eisai Co - European Commission Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizum..
AQ
2021Eisai - European Commission Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab)..
AQ
2021Merck and Ridgeback Biotherapeutics Provide Update on Results from MOVe-OUT Study of Mo..
AQ
2021European Commission Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) for P..
BU
2021European Commission Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) as Fi..
BU
2021Merck and Ridgeback Biotherapeutics Provide Update on Results from MOVe-OUT Study of Mo..
BU
2021Merck to Present at the 4th Annual Evercore ISI HealthCONx Conference
BU
2021MERCK : Gilead and Merck Announce Temporary Pause in Enrollment for Phase 2 Study Evaluati..
PU
2021Health Canada Approves KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy for t..
AQ
2021Merck Completes Acquisition of Acceleron Pharma Inc.
BU
2021Merck Completes Tender Offer to Acquire Acceleron Pharma Inc.
AQ
2021Supplying Covid-19 Pills At Lower Cost Is Only Part of What Poorer Countries Need
AQ
2021Merck Completes Tender Offer to Acquire Acceleron Pharma Inc.
BU
2021Merck Provides Update on Phase 2 Clinical Trial of Once-Weekly Investigational Combinat..
BU
2021FDA Approves Merck's KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Certain Patients..
BU
1  2  3  4  5  6  7  8  9  10Next
Upcoming event on MERCK & CO., INC.
02/03/22